Northwest Bank & Trust Co Purchases Shares of 7,677 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Northwest Bank & Trust Co bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 7,677 shares of the medical equipment provider’s stock, valued at approximately $934,000.

Several other institutional investors have also recently made changes to their positions in the company. PFG Advisors raised its position in shares of Zimmer Biomet by 4.6% in the 4th quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock worth $231,000 after acquiring an additional 84 shares in the last quarter. Quent Capital LLC increased its position in Zimmer Biomet by 21.6% during the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 92 shares in the last quarter. Chicago Partners Investment Group LLC increased its position in Zimmer Biomet by 3.3% during the 4th quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock valued at $349,000 after buying an additional 92 shares in the last quarter. Stokes Family Office LLC increased its position in Zimmer Biomet by 4.1% during the 3rd quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock valued at $280,000 after buying an additional 99 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its position in Zimmer Biomet by 15.6% during the 3rd quarter. Parkside Financial Bank & Trust now owns 756 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 102 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH traded up $0.22 during trading hours on Friday, hitting $107.19. The stock had a trading volume of 1,611,412 shares, compared to its average volume of 1,425,935. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $147.50. The firm has a market capitalization of $22.05 billion, a PE ratio of 23.20, a PEG ratio of 1.93 and a beta of 1.02. The stock has a fifty day moving average price of $118.61 and a 200 day moving average price of $121.84.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the previous year, the company posted $1.89 earnings per share. Zimmer Biomet’s revenue was up 3.2% compared to the same quarter last year. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio is presently 20.78%.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Barclays reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research report on Friday, May 31st. Oppenheimer raised their price objective on Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Citigroup raised their price objective on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Truist Financial reduced their target price on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a report on Friday, May 3rd. Finally, Evercore ISI lifted their target price on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $133.75.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.